Shivalik Rasayan Limited
SHIVALIK.NS
₹384.90
▲ 20.00%
Shivalik Rasayan shares hit the roof, locking in a 20% upper-circuit surge to ₹384.90 after the company bagged a Certificate of Suitability (CEP) for its API Pirfenidone from European pharma regulator EDQM, opening the door to regulated export markets. The move echoes past instances where regulatory nods — like a previous USFDA API approval — have triggered similarly sharp single-day rallies of around 14.5% for the stock. Even with today's pop, the small-cap pharma name, with a market cap of roughly ₹410 crore, remains down 28-32% over the past year and is trading well off its 52-week high of ₹639, though it still trades at a notable 47% discount to its peer group's median P/E of 63.66x at 33.74x. Longer-term CAGR numbers tell a similarly rough story, with the stock down between 15% and 19% annually across the 1, 2, 5 and 10-year windows, meaning today's spike is a sharp reversal rather than a trend confirmation.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| -21.42% | -17.27% | -17.94% | -17.94% |
Related News
No comments:
Post a Comment